These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31454764)

  • 1. Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab.
    Moreira Ferreira VF; Meredith D; Stankiewicz JM
    Neurol Neuroimmunol Neuroinflamm; 2019 Sep; 6(5):. PubMed ID: 31454764
    [No Abstract]   [Full Text] [Related]  

  • 2. Endocarditis following ocrelizumab in relapsing-remitting MS.
    Faissner S; Schwake C; Gotzmann M; Mügge A; Schmidt S; Gold R
    Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32014890
    [No Abstract]   [Full Text] [Related]  

  • 3. Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab.
    Barton J; Hardy TA; Riminton S; Reddel SW; Barnett Y; Coles A; Barnett MH
    Neurology; 2017 Mar; 88(10):1004-1006. PubMed ID: 28179462
    [No Abstract]   [Full Text] [Related]  

  • 4. Parvovirus B19 infection in a patient with multiple sclerosis treated with ocrelizumab.
    Lattanzi S; Carlini G; Acciarri MC; Danni M; Silvestrini M
    Acta Neurol Belg; 2020 Feb; 120(1):231-232. PubMed ID: 31654393
    [No Abstract]   [Full Text] [Related]  

  • 5. Ocrelizumab (Ocrevus) for MS.
    Med Lett Drugs Ther; 2017 Jun; 59(1523):98-101. PubMed ID: 28609424
    [No Abstract]   [Full Text] [Related]  

  • 6. Two cases of meningitis associated with ocrelizumab therapy.
    Theriault M; Solomon AJ
    Mult Scler Relat Disord; 2020 Feb; 38():101866. PubMed ID: 31821962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis.
    Cohen BA
    Neurology; 2019 Feb; 92(9):435-436. PubMed ID: 30635476
    [No Abstract]   [Full Text] [Related]  

  • 8. Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature.
    Zanetta C; Robotti M; Nozzolillo A; Sangalli F; Liberatore G; Nobile-Orazio E; Filippi M; Moiola L
    J Neurol Sci; 2020 Feb; 409():116603. PubMed ID: 31811986
    [No Abstract]   [Full Text] [Related]  

  • 9. Half-dose ocrelizumab in selected patients with relapsing-remitting multiple sclerosis.
    Algahtani H; Shirah B; Alqahtani A; Abdelghaffar N; Makki S
    Acta Neurol Belg; 2024 Feb; 124(1):303-306. PubMed ID: 37301802
    [No Abstract]   [Full Text] [Related]  

  • 10. Dermatographism associated with ocrelizumab.
    Raynowska J; Graves JS
    Mult Scler Relat Disord; 2020 Nov; 46():102505. PubMed ID: 32979732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    Hauser SL; Bar-Or A; Comi G; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Montalban X; Rammohan KW; Selmaj K; Traboulsee A; Wolinsky JS; Arnold DL; Klingelschmitt G; Masterman D; Fontoura P; Belachew S; Chin P; Mairon N; Garren H; Kappos L;
    N Engl J Med; 2017 Jan; 376(3):221-234. PubMed ID: 28002679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocrelizumab: A New B-cell Therapy for Relapsing Remitting and Primary Progressive Multiple Sclerosis.
    Stahnke AM; Holt KM
    Ann Pharmacother; 2018 May; 52(5):473-483. PubMed ID: 29232960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fulminant Hepatitis Associated With Echovirus 25 During Treatment With Ocrelizumab for Multiple Sclerosis.
    Nicolini LA; Canepa P; Caligiuri P; Mikulska M; Novi G; Viscoli C; Uccelli A
    JAMA Neurol; 2019 Jul; 76(7):866-867. PubMed ID: 30958517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral pericarditis following ocrelizumab in a multiple sclerosis patient.
    Miele G; Abbadessa G; Maida E; Bonavita S
    Neurol Sci; 2023 Aug; 44(8):2947-2949. PubMed ID: 37095363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocrelizumab in pediatric patients with MS: Efficacy, tolerability, and safety.
    Zeydan B
    Eur J Paediatr Neurol; 2023 Mar; 43():A1. PubMed ID: 36990951
    [No Abstract]   [Full Text] [Related]  

  • 16. Dengue fever in a multiple sclerosis patient taking Ocrelizumab.
    Guerra T; Bollo L; Trojano M; Iaffaldano P
    Mult Scler; 2021 Nov; 27(13):2116-2118. PubMed ID: 34449289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psoriasiform dermatitis following ocrelizumab in relapsing-remitting multiple sclerosis: Case report and literature review.
    Emma C; Vesela P; Kay P; Huseyin H; Alison H; Mara S; Floriana A; Sara C
    Mult Scler; 2024 Jun; 30(7):893-897. PubMed ID: 38385208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum sickness in a multiple sclerosis patient treated with ocrelizumab.
    Mantero V; Cordano C; Balgera R; Basilico P; Novi G; Salmaggi A
    J Neurol; 2024 Feb; 271(2):727-728. PubMed ID: 37907726
    [No Abstract]   [Full Text] [Related]  

  • 19. Acute pancreatitis after ocrelizumab treatment for relapsing remitting multiple sclerosis.
    Adamec I; Reiner Ž; Pećin I; Šućur N; Godan Hauptman A; Barun B; Gabelić T; Habek M
    Mult Scler Relat Disord; 2020 Oct; 45():102381. PubMed ID: 32653735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocrelizumab-associated enteritis in patients with multiple sclerosis: an emerging safety issue.
    Viti V; Zanetta C; Capra R; Municchi A; Rocca MA; Filippi M
    J Neurol; 2024 Sep; 271(9):6368-6376. PubMed ID: 38992209
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.